In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Agenus (AGEN – Research Report), with a price target of $8.00. The company’s shares opened today at $1.23.
Mamtani covers the Healthcare sector, focusing on stocks such as Agenus, Novavax, and Madrigal Pharmaceuticals. According to TipRanks, Mamtani has an average return of -23.4% and a 22.60% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agenus with a $7.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Agenus’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $25.3 million and a GAAP net loss of $69.02 million. In comparison, last year the company earned a revenue of $20.93 million and had a GAAP net loss of $46.43 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus (AGEN) Company Description:
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Read More on AGEN:
- Biotech Alert: Searches spiking for these stocks today
- Billionaire Steve Cohen Loads Up on These 2 ‘Strong Buy’ Penny Stocks — Here’s Why Wall Street Sees Over 500% Upside Potential
- Agenus reports Q2 EPS (20c), consensus (20c)
- AGEN Earnings this Week: How Will it Perform?
- Jasper Therapeutics appoints Carlos as SVP, Marcantonio as VP
